Detalhe da pesquisa
1.
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2.
Cancer Immunol Immunother
; 70(5): 1255-1262, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33130956
2.
Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort.
Cancer Immunol Immunother
; 69(8): 1605-1613, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32307579
3.
Drug conjugates such as Antibody Drug Conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice.
Int J Mol Sci
; 13(12): 16020-45, 2012 Nov 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-23443108
4.
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.
Lung Cancer
; 169: 77-83, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35660972
5.
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
J Clin Oncol
; 39(26): 2872-2880, 2021 09 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34251873
6.
Image analysis in posttreatment non-small cell lung cancer surveillance: specialists' interpretations reviewed by the thoracic multidisciplinary tumor board.
Multidiscip Respir Med
; 14: 34, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31827794
7.
Comparing Two Imaging Methods for Follow-Up of Lung Cancer Treatment: A Randomized Pilot Study.
Ann Thorac Surg
; 107(2): 430-435, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30292847